

Clinical Policy: AbobotulinumtoxinA (Dysport)

Reference Number: CP.PHAR.230

Effective Date: 07.01.16

Last Review Date: 05.21

Line of Business: Commercial, HIM, Medicaid

[Coding Implications](#)

[Revision Log](#)

See [Important Reminder](#) at the end of this policy for important regulatory and legal information.

Description

AbobotulinumtoxinA (Dysport®) is an acetylcholine release inhibitor and a neuromuscular blocking agent.

FDA Approved Indication(s)

Indication	Adults	Pediatrics	Treatment	Prophylaxis
Cervical dystonia (focal dystonia)	X		X	
Upper/lower limb spasticity (includes CP)	X	X	X	
Off-Label Uses				
Overactive bladder	X		X	
Urinary incontinence	X		X	
Migraine	X			X
Axillary hyperhidrosis	X		X	
Blepharospasm (focal dystonia)	X		X	
Strabismus	X		X	
Sialorrhea	X			
Laryngeal dystonia*	X		X	
Oromandibular dystonia*	X		X	
Upper extremity dystonia*	X	X	X	
Upper extremity essential tremor*	X		X	
Esophageal achalasia	X		X	
HD and IAS achalasia	X	X	X	
Chronic anal fissure	X		X	

Abbreviations: cerebral palsy (CP); Hirschsprung disease (HD), internal anal sphincter (IAS) achalasia.

*See criteria set entitled Focal Dystonia and Essential Tremor

Dysport is indicated:

- For the treatment of cervical dystonia (CD) in adults
- For the treatment of spasticity in patients 2 years of age and older
- For temporary improvement in the appearance of moderate to severe glabellar lines associated with procerus and corrugator muscle activity in adult patients < 65 years of age [benefit exclusion]

Policy/Criteria

Provider must submit documentation (such as office chart notes, lab results or other clinical information) supporting that member has met all approval criteria.

Index

I. Initial Approval Criteria

- A. Cervical Dystonia (*focal dystonia*)
- B. Upper and Lower Limb Spasticity (*includes cerebral palsy*)
- C. Overactive Bladder and Urinary Incontinence (off-label)
- D. Chronic Migraine (off-label)
- E. Axillary Hyperhidrosis (*excessive underarm sweating*) (off-label)
- F. Blepharospasm (*focal dystonia - abnormal eyelid muscle contraction*) (off-label)
- G. Strabismus (*eye misalignment*) (off-label)
- H. Sialorrhea (off-label)
- I. Focal Dystonia and Essential Tremor (off-label)
- J. Esophageal Achalasia (off-label)
- K. Hirschsprung Disease and Internal Anal Sphincter Achalasia (off-label)
- L. Chronic Anal Fissure (off-label)
- M. Other diagnoses/indications

II. Continued Approval Criteria

- A. Chronic Migraine
- B. Esophageal Achalasia
- C. Cervical Dystonia and Upper/Lower Limb Spasticity
- D. All Other Indications in Section I
- E. Other diagnoses/indications

III. Diagnoses/Indications for which coverage is NOT authorized:

IV. Appendices

V. Dosage and Administration

VI. Product Availability

VII. References

It is the policy of health plans affiliated with Centene Corporation[®] that Dysport is **medically necessary** when one of the following criteria are met:

I. Initial Approval Criteria

A. Cervical Dystonia (*focal dystonia*) (must meet all):

- 1. Diagnosis of CD;
- 2. Prescribed by or in consultation with a neurologist, orthopedist, or physiatrist;
- 3. Age \geq 18 years;
- 4. Member is experiencing involuntary contractions of the neck and shoulder muscles (e.g., splenius, sternocleidomastoid, levator scapulae, scalene, trapezius, semispinalis capitis) resulting in abnormal postures or movements of the neck, shoulders or head;
- 5. Contractions are causing pain and functional impairment;
- 6. Member meets both of the following (a and b):
 - a. Dysport is not prescribed concurrently with other botulinum toxin products;
 - b. Botulinum toxin therapy for cosmetic or medical conditions has not been administered within the last 12 weeks;
- 7. Treatment plan details number of Units per indication and treatment session;
- 8. Dose does not exceed 500 Units per treatment session.

Approval duration:

Medicaid/HIM – 12 weeks (single treatment session)

Commercial – 6 months

B. Upper and Lower Limb Spasticity (*includes cerebral palsy*) (must meet all):

1. Diagnosis of upper or lower limb spasticity (e.g., associated with paralysis, central nervous system demyelinating diseases such as multiple sclerosis, cerebral palsy, stroke);
2. Prescribed by or in consultation with a neurologist, orthopedist, or physiatrist;
3. Age \geq 2 years;
4. Member meets both of the following (a and b):
 - a. Dysport is not prescribed concurrently with other botulinum toxin products;
 - b. Botulinum toxin therapy for cosmetic or medical conditions has not been administered within the last 12 weeks;
5. Treatment plan details number of Units per indication and treatment session;
6. Request meets one of the following (a or b):
 - a. Age \geq 18 years (i, ii, or iii):
 - i. Upper limb spasticity: Dose does not exceed 1,000 Units per treatment session;
 - ii. Lower limb spasticity: Dose does not exceed 1,500 Units per treatment session;
 - iii. Upper and lower limb spasticity: Dose does not exceed 1,500 Units per treatment session staying within per limb dosing guidelines;
 - b. Age \geq 2 years to $<$ 18 years (i, ii, or iii):
 - i. Upper limb spasticity: Dose does not exceed the lower of 16 Units/kg or 640 Units;
 - ii. Lower limb spasticity: Dose does not exceed the lower of 15 Units/kg (one limb), 30 Units/kg (two limbs), or 1,000 Units per treatment session;
 - iii. Upper and lower limb spasticity: Dose does not exceed the lower of 30 Units/kg or 1,000 Units per treatment session staying within per limb dosing guidelines.

Approval duration:

Medicaid/HIM – 12 weeks (single treatment session)

Commercial – 6 months

C. Overactive Bladder and Urinary Incontinence (off-label) (must meet all):

1. Diagnosis of one of the following (a or b):
 - a. OAB and member's history is positive for urinary urgency, frequency, and nocturia with or without incontinence;
 - b. Urinary incontinence and member's history is positive for an associated neurologic condition (e.g., spinal cord injury, multiple sclerosis);
2. Prescribed by or in consultation with a neurologist or urologist;
3. Age \geq 18 years;
4. Failure of a trial of at least two anticholinergic agents and one oral beta-3 agonist medication (*see Appendix B*), each used for at least 30 days, unless clinically significant adverse effects are experienced or all are contraindicated;

5. Member meets both of the following (a and b):
 - b. Dysport is not prescribed concurrently with other botulinum toxin products;
 - c. Botulinum toxin therapy for cosmetic or medical conditions has not been administered within the last 12 weeks;
6. Treatment plan details number of Units per indication and treatment session;
7. Dose does not exceed 250 Units per treatment session.

Approval duration:

Medicaid/HIM – 12 weeks (single treatment session)

Commercial – 6 months or to member's renewal date, whichever is longer

D. Chronic Migraine (off-label) (must meet all):

1. Diagnosis of chronic migraine (i.e., ≥ 15 headache days per month for at least 3 months with headache lasting 4 hours a day or longer);
2. Prescribed by or in consultation with a neurologist or pain specialist;
3. Age ≥ 18 years;
4. Failure of at least 2 of the following oral migraine preventative therapies, each for 8 weeks and from different therapeutic classes, unless clinically significant adverse effects are experienced or all are contraindicated (a, b, or c):
 - a. Antiepileptics (e.g., divalproex sodium, sodium valproate, topiramate);
 - b. Beta-blockers (e.g., metoprolol, propranolol, timolol);
 - c. Antidepressants (e.g., amitriptyline, venlafaxine);
5. Member meets all of the following (a, b, and c):
 - a. Dysport is not prescribed concurrently with injectable CGRP inhibitors (e.g., Aimovig[®], Ajoovy[®], Emgality[®]);
 - b. Dysport is not prescribed concurrently with other botulinum toxin products;
 - d. Botulinum toxin therapy for cosmetic or medical conditions has not been administered within the last 12 weeks;
6. Treatment plan details number of Units per indication and treatment session;
7. Dose does not exceed 250 Units per treatment session.

Approval duration:

Medicaid/HIM – 24 weeks (two 12-week treatment sessions)

Commercial – 6 months or to member's renewal date, whichever is longer

E. Primary Axillary Hyperhidrosis (*excessive underarm sweating*) (off-label) (must meet all):

**The treatment of hyperhidrosis is a benefit exclusion for HIM*

1. Diagnosis of primary axillary hyperhidrosis;
2. Prescribed by or in consultation with a neurologist or dermatologist;
3. Age ≥ 18 years;
4. Failure of a 6-month trial of topical aluminum chloride, unless contraindicated or clinically significant adverse effects are experienced;
5. Member meets both of the following (a and b):
 - a. Dysport is not prescribed concurrently with other botulinum toxin products;
 - b. Botulinum toxin therapy for cosmetic or medical conditions has not been administered within the last 12 weeks;
6. Treatment plan details number of Units per indication and treatment session;

7. Dose does not exceed 200 Units per treatment session.

Approval duration:

Medicaid – 12 weeks (single treatment session)

HIM – Benefit Exclusion (Not Approvable)

Commercial – 6 months or to member’s renewal date, whichever is longer

F. Blepharospasm (*focal dystonia - abnormal eyelid muscle contraction*) (off-label) (must meet all):

1. Diagnosis of blepharospasm;
2. Prescribed by or in consultation with a neurologist or ophthalmologist;
3. Age \geq 18 years;
4. Member is experiencing significant disability in daily functional activities due to interference with vision;
5. Member meets both of the following (a and b):
 - a. Dysport is not prescribed concurrently with other botulinum toxin products;
 - b. Botulinum toxin therapy for cosmetic or medical conditions has not been administered within the last 12 weeks;
6. Treatment plan details number of Units per indication and treatment session;
7. Dose does not exceed 60 Units per treatment session.

Approval duration:

Medicaid/HIM – 12 weeks (single treatment session)

Commercial – 6 months or to member’s renewal date, whichever is longer

G. Strabismus (*eye misalignment*) (off-label) (must meet all):

1. Diagnosis of one of the following (a, b, or c):
 - a. Vertical strabismus (superior and inferior rectus muscles, superior and inferior oblique muscles);
 - b. Horizontal strabismus (medical and lateral rectus muscles) (i or ii):
 - i. Horizontal strabismus $<$ 20 prism diopters;
 - ii. Horizontal strabismus 20 to 50 prism diopters;
 - c. Persistent sixth cranial nerve (VI; abducens nerve) palsy of \geq one month involving the lateral rectus muscle;
2. Prescribed by or in consultation with a neurologist or ophthalmologist;
3. Age \geq 12 years;
4. Member meets both of the following (a and b):
 - a. Dysport is not prescribed concurrently with other botulinum toxin products;
 - b. Botulinum toxin therapy for cosmetic or medical conditions has not been administered within the last 12 weeks;
5. Treatment plan details number of Units per indication and treatment session;
6. Dose does not exceed 20 Units per treatment session.

Approval duration:

Medicaid/HIM – 12 weeks (single treatment session)

Commercial – 6 months or to member’s renewal date, whichever is longer

H. Chronic Sialorrhea (off-label) (must meet all):

1. Diagnosis of chronic sialorrhea for at least the last three months due to one of the following (a or b):
 - a. Underlying neurologic disorder (e.g., Parkinson disease, atypical parkinsonism, stroke, traumatic brain injury, cerebral palsy, amyotrophic lateral sclerosis);
 - b. Craniofacial abnormality (e.g., Goldenhar syndrome);
2. Prescribed by or in consultation with a neurologist or physiatrist;
3. Age \geq 18 years;
4. Failure of at least one anticholinergic drug (*see Appendix B*), unless clinically significant adverse effects are experienced or all are contraindicated;
5. Member meets both of the following (a and b):
 - a. Dysport is not prescribed concurrently with other botulinum toxin products;
 - b. Botulinum toxin therapy for cosmetic or medical conditions has not been administered within the last 16 weeks;
6. Treatment plan provided detailing number of Units per indication and treatment session;
7. Dose does not exceed 250 Units per treatment session;

Approval duration:

Medicaid/HIM – 16 weeks (single treatment session)

Commercial – 6 months

I. Focal Dystonia and Essential Tremor (off-label) (must meet all):

1. Diagnosis of one of the following (a, b, c, or d):
 - a. Laryngeal dystonia;
 - b. Oromandibular dystonia (OMD);
 - c. Upper extremity (UE) dystonia;
 - d. UE essential tremor;
2. Prescribed by or in consultation with a neurologist, ENT specialist, orthopedist, or physiatrist;
3. Age meets one of the following (a or b):
 - a. For upper extremity dystonia: Age \geq 2 years;
 - b. For all other indications: Age \geq 18 years;
4. For upper extremity dystonia: Failure of a trial of carbidopa/levodopa or trihexyphenidyl (*see Appendix B*), unless clinically significant adverse effects are experienced or both are contraindicated;
5. Member meets both of the following (a and b):
 - a. Dysport is not prescribed concurrently with other botulinum toxin products;
 - b. Botulinum toxin therapy for cosmetic or medical conditions has not been administered within the last 12 weeks;
6. Treatment plan details number of Units per indication and treatment session;
7. Request meets one of the following (a or b):
 - a. Laryngeal dystonia: Dose does not exceed 45 Units per treatment session;
 - b. OMD: Dose does not exceed 100 Units per treatment session;
 - c. UE dystonia, UE essential tremor: Dose is supported by practice guidelines or peer-reviewed literature for the relevant off-label use and member age (*prescriber must submit supporting evidence; Units per treatment session does not exceed the*

lower of 16 Units/kg body weight or 640 Units for pediatrics, or 1,000 Units for adults).

Approval duration:

Medicaid/HIM – 12 weeks (single treatment session)

Commercial – 6 months or to member’s renewal date, whichever is longer

J. Esophageal Achalasia (off-label) (must meet all):

1. Diagnosis of esophageal achalasia;
2. Prescribed by or in consultation with a gastroenterologist;
3. Age \geq 18 years;
4. Member is not a candidate for pneumatic dilation or laparoscopic surgical myotomy (e.g., due to age, comorbidity);
5. Member meets both of the following (a and b):
 - a. Dysport is not prescribed concurrently with other botulinum toxin products;
 - b. Botulinum toxin therapy for cosmetic or medical conditions has not been administered within the last 12 weeks;
6. Treatment plan details number of Units per indication and treatment session;
7. Dose does not exceed 250 Units per treatment session.

Approval duration:

Medicaid/HIM – 12 weeks (single treatment session)

Commercial – 6 months or to member’s renewal date, whichever is longer

K. Hirschsprung Disease, Internal Anal Sphincter Achalasia (off-label) (must meet all):

1. Diagnosis of one of the following (a or b):
 - a. Hirschsprung disease (HD) and (i or ii):
 - i. Member has an HD subtype known as ultra-short segment HD;
 - ii. Dysport is prescribed for constipation post-surgery;
 - b. Internal anal sphincter (IAS) achalasia;
2. Prescribed by or in consultation with a gastroenterologist;
3. Age \geq 3 years;
4. Failure of a trial of stool softeners and laxatives (*see Appendix B*), unless clinically adverse effects are experienced or all are contraindicated;
5. Member meets both of the following (a and b):
 - a. Dysport is not prescribed concurrently with other botulinum toxin products;
 - b. Botulinum toxin therapy for cosmetic or medical conditions has not been administered within the last 12 weeks;
6. Treatment plan details number of Units per indication and treatment session;
7. Dose does not exceed 200 Units per treatment session.

Approval duration:

Medicaid/HIM – 12 weeks (single treatment session)

Commercial – 6 months or to member’s renewal date, whichever is longer

L. Chronic Anal Fissure (off-label) (must meet all):

1. Diagnosis of chronic anal fissure;
2. Prescribed by or in consultation with a gastroenterologist or colorectal surgeon;
3. Age \geq 18 years;

4. Failure of nitroglycerin ointment and either oral/topical nifedipine or diltiazem (*see Appendix B*), unless contraindicated or clinically significant adverse effects are experienced;
5. Member meets both of the following (a and b):
 - a. Dysport is not prescribed concurrently with other botulinum toxin products;
 - b. Botulinum toxin therapy for cosmetic or medical conditions has not been administered within the last 12 weeks;
6. Treatment plan details number of Units per indication and treatment session;
7. Dose does not exceed 100 Units per treatment session.

Approval duration:

Medicaid/HIM – 12 weeks (single treatment session)

Commercial – 6 months or to member’s renewal date, whichever is longer

M. Other diagnoses/indications

1. Refer to the off-label use policy for the relevant line of business if diagnosis is NOT specifically listed under section III (Diagnoses/Indications for which coverage is NOT authorized): CP.CPA.09 for commercial, HIM.PA.154 for health insurance marketplace, and CP.PMN.53 for Medicaid.

II. Continued Approval

A. Chronic Migraine (must meet all):

1. Currently receiving medication via Centene benefit or member has previously met all initial approval criteria;
2. If receipt of ≥ 2 Dysport treatment sessions, member has experienced and maintained a 30% reduction in monthly migraine headache frequency from baseline;
3. Member meets all of the following (a, b, and c):
 - a. Dysport is not prescribed concurrently with injectable CGRP inhibitors (e.g., Aimovig, Ajovy, Emgality);
 - b. Dysport is not prescribed concurrently with other botulinum toxin products;
 - c. Botulinum toxin therapy for cosmetic or medical conditions has not been administered within the last 12 weeks;
4. Treatment plan details number of Units per indication and treatment session;
5. If request is for a dose increase, new dose does not exceed 250 Units per treatment session.

Approval duration:

Medicaid/HIM – 24 weeks (two 12-week treatment sessions)

Commercial – 6 months or to member’s renewal date, whichever is longer

B. Esophageal Achalasia (must meet all):

1. Currently receiving medication via Centene benefit or member has previously met all initial approval criteria;
2. Member is responding positively to therapy;
3. Member meets all of the following (a, b, and c):
 - a. Dysport is not prescribed concurrently with other botulinum toxin products;
 - b. Botulinum toxin therapy for cosmetic or medical conditions has not been administered within the last 12 weeks;

- c. If member has previously received ≥ 2 Dysport treatment sessions for esophageal achalasia, it has been at least 24 weeks since the last treatment session;
4. Treatment plan details number of Units per indication and treatment session;
5. If request is for a dose increase, new dose does not exceed 250 Units per treatment session.

Approval duration:

Medicaid/HIM –

- 2nd treatment session: 12 weeks (single treatment session);
- 3rd treatment session and beyond: 24 weeks (single treatment session)

Commercial – 6 months or to member's renewal date, whichever is longer

C. Cervical Dystonia and Upper/Lower Limb Spasticity (must meet all):

1. Currently receiving medication via Centene benefit or member has previously met initial approval criteria;
2. Member is responding positively to therapy;
3. Member meets both of the following (a and b):
 - a. Dysport is not prescribed concurrently with other botulinum toxin products;
 - b. Botulinum toxin therapy for cosmetic or medical conditions has not been administered within the last 12 weeks;
4. Treatment plan details number of Units per indication and treatment session;
5. If request is for a dose increase, request meets one of the following (a or b):
 - a. Age ≥ 18 years (i, ii, iii, or iv):
 - i. CD: Dose does not exceed an increase of 250 Units per treatment session up to a total of 1,000 Units per treatment session;
 - ii. Upper limb spasticity: Dose does not exceed 1,000 Units per treatment session;
 - iii. Lower limb spasticity: Dose does not exceed 1,500 Units per treatment session;
 - iv. Upper and lower limb spasticity: Dose does not exceed 1,500 Units per treatment session staying within per limb dosing guidelines;
 - b. Age ≥ 2 years to < 18 years (i, ii, or iii):
 - i. Upper limb spasticity: Dose does not exceed the lower of 16 Units/kg or 640 Units;
 - ii. Lower limb spasticity: Dose does not exceed the lower of 15 Units/kg (one limb), 30 Units/kg (two limbs), or 1,000 Units per treatment session;
 - iii. Upper and lower limb spasticity: Dose does not exceed the lower of 30 Units/kg or 1,000 Units per treatment session staying within per limb dosing guidelines.

Approval duration:

Medicaid/HIM – 12 weeks (single treatment session)

Commercial – 12 months

D. All Other Indications in Section I (off-label) (must meet all):

**The treatment of hyperhidrosis is a benefit exclusion for HIM.*

1. Currently receiving medication via Centene benefit or member has previously met initial approval criteria;

2. Member is responding positively to therapy;
3. Member meets both of the following (a and b):
 - a. Dysport is not prescribed concurrently with other botulinum toxin products;
 - b. Botulinum toxin therapy for cosmetic or medical conditions has not been administered within the last 12 weeks;
4. Treatment plan details number of Units per indication and treatment session;
5. If request is for a dose increase, request meets one of the following (a or b):
 - a. OAB/urinary incontinence, sialorrhea: Dose does not exceed 250 Units per treatment session;
 - b. AH, HD, IAS achalasia: Dose does not exceed 200 Units per treatment session;
 - c. Blepharospasm: Dose does not exceed 60 Units per treatment session;
 - d. Strabismus: Dose does not exceed 20 Units per treatment session;
 - e. Laryngeal dystonia: Dose does not exceed 45 Units per treatment session;
 - f. OMD, CAF: Dose does not exceed 100 Units per treatment session;

Approval duration:

Medicaid/HIM –

- Sialorrhea: 16 weeks (single treatment session);
- All other indications: 12 weeks (single treatment session)

Commercial – 12 months

A. Other diagnoses/indications (1 or 2):

1. Currently receiving medication via Centene benefit and documentation supports positive response to therapy;

Approval duration: 12 weeks (single treatment session); or

2. Refer to the off-label use policy for the relevant line of business if diagnosis is NOT specifically listed under section III (Diagnoses/Indications for which coverage is NOT authorized): CP.CPA.09 for commercial, HIM.PA.154 for health insurance marketplace, and CP.PMN.53 for Medicaid.

III. Diagnoses/Indications for which coverage is NOT authorized:

- A.** Non-FDA approved indications, which are not addressed in this policy, unless there is sufficient documentation of efficacy and safety according to the off label use policies – CP.CPA.09 for commercial, HIM.PA.154 for health insurance marketplace, and CP.PMN.53 for Medicaid, or evidence of coverage documents;
- B.** Cosmetic treatment of hyperfunctional wrinkles of the upper face including glabellar frown lines, deep forehead wrinkles and periorbital wrinkles (crow's feet);
- C.** Episodic migraine (\leq 14 headache days per month): Safety and efficacy have not been established per the package insert;
- D.** Total treatment dose per session does not exceed the lower of 30 Units/kg body weight or 1,000 Units for pediatrics and 1,500 Units for adults.

IV. Appendices/General Information

Appendix A: Abbreviation/Acronym Key

CD: cervical dystonia

FDA: Food and Drug Administration

HD: Hirschsprung disease

IAS: internal anal sphincter

MS: multiple sclerosis

OAB: overactive bladder

OMD: oromandibular dystonia
SCI: spinal cord injury

UE: upper extremity

Appendix B: Therapeutic Alternatives

This table provides a listing of preferred alternative therapy recommended in the approval criteria. The drugs listed here may not be a formulary agent for all relevant lines of business and may require prior authorization.

Drug Name	Dosing Regimen	Dose Limit/ Maximum Dose
<i>Overactive bladder, urinary incontinence</i>		
oxybutynin (Ditropan [®] /XL, Gelnique [®]) (anticholinergic agent)	<ul style="list-style-type: none"> • Immediate-release tablets: 5 mg orally two to three times daily • Extended-release tablets: 5-10 mg orally once daily • Topical gel: Apply contents of one sachet topically once daily 	<ul style="list-style-type: none"> • Immediate-release: 20 mg/day • Extended-release: 30 mg/day • Gel: one sachet/day
tolterodine tartrate (Detrol [®] /LA) (anticholinergic agent)	<ul style="list-style-type: none"> • Immediate-release tablets: 2 mg orally twice daily • Extended-release tablets: 4 mg orally once daily 	4 mg/day
Myrbetriq [®] (mirabegron) (beta-3 agonist)	25 mg orally once daily	50 mg/day
<i>Chronic migraine</i>		
<i>Examples of oral migraine preventive therapies -</i> <ul style="list-style-type: none"> • Anticonvulsants: divalproex (Depakote[®]), topiramate (Topamax[®]) • Beta blockers: propranolol (Inderal[®]), metoprolol (Lopressor[®]), timolol • Antidepressants/tricyclic antidepressants: amitriptyline (Elavil[®]), venlafaxine (Effexor[®]) 	<i>Refer to prescribing information for dosing regimens.</i>	<i>Refer to prescribing information</i>
<i>Primary axillary hyperhidrosis</i>		
Drysol [®] (aluminum chloride)	Apply topically once daily	One application/day
<i>Sialorrhea: examples of anticholinergic drugs</i>		
glycopyrrolate (Glycate [®] oral tablets, Cuvposa [®] oral solution)	<ul style="list-style-type: none"> • Adults: 1 mg PO TID (Off-label: Lakraj 2013) 	See regimen information

Drug Name	Dosing Regimen	Dose Limit/ Maximum Dose
	<ul style="list-style-type: none"> • Pediatrics: chronic drooling: children \geq 3 years and adolescents \leq 16 years: oral solution (Cuvposa): 20 mcg/kg/dose 3 times daily, titrate in increments of 20 mcg/kg/dose every 5 to 7 days as tolerated to response up to a maximum dose of 100 mcg/kg/dose 3 times daily; not to exceed 1,500 to 3,000 mcg/dose. (FDA labeled) 	
benztropine mesylate (oral tablets - 0.5 mg, 1 mg, 2 mg)	Mean doses of 3.8 mg/day have been used in adults and pediatrics \geq 4 years. Benztropine typically is administered in divided doses titrating up as needed. (Off-label - Sridharan 2018, Lakraj 2013; Micromedex, package insert)	See regimen information
Dystonia		
carbidopa/levodopa (Sinemet [®] , Duopa [®] , Rytary [®])	25 mg/100 mg PO QD, and increase by 1 tablet every 3 to 5 days.	1,200 mg/day of levodopa
trihexyphenidyl	30 mg PO QD	30 mg/day
HD, IAS achalasia		
Dulcolax [®] (bisacodyl)	5 to 15 mg PO or 10 mg PR QD	30 mg/day
MiraLax [®] (Polyethylene glycol 3350)	17 grams of polyethylene glycol 3350 in 4-8 oz water by mouth once daily	17 grams/day
Colace [®] (Docusate sodium)	50-200 mg PO QD-QID	200 mg/day
Chronic anal fissure		
nitroglycerin 0.2% ointment (Rectiv [®])	15 to 30 mg (2.5 to 5 cm as squeezed from the tube, about 1 to 2 inches), applied topically to skin every 8 hours while awake and at bedtime; application frequency may be increased to every 6 hours if needed; alternatively, a regimen providing a 12-hour nitrate-free interval may be used; apply dosage once each morning, then 6 hours later	75 mg (12.5 cm as squeezed from the tube)/day
nifedipine or diltiazem (oral or topical ointment/gel-compounded)	PO: At provider discretion Intra-anal: 0.2% ointment or gel, applied around fissure(s) 2 times daily for 6-8 weeks	Varies

Therapeutic alternatives are listed as Brand name[®] (generic) when the drug is available by brand name only and generic (Brand name[®]) when the drug is available by both brand and generic.

Appendix C: Contraindications and Boxed Warnings

- Contraindication(s):
 - Hypersensitivity to any botulinum toxin preparation or excipients
 - Hypersensitivity to cow’s milk protein
 - Infection at the proposed injection site
- Boxed warning(s): distant spread of toxin effect

Appendix D: Botulinum Toxin Product Interchangeability

- Potency Units of Dysport are not interchangeable with other botulinum toxin product preparations (e.g., Botox[®], Myobloc[®], Xeomin[®]).

Appendix E: Guideline Support for Botulinum Toxin Use

Indication	Guideline
<i>Focal Dystonia* and Essential Tremor, and Headache</i>	
Blepharospasm, cervical dystonia, adult spasticity, and headache	Academy of Neurology (2016)
Migraine prevention	American Academy of Neurology and the American Headache Society. Neurology (2012)
Laryngeal dystonia	American Academy of Otolaryngology-Head and Neck Surgery Foundation (2018); American Academy of Neurology (2008)
Oromandibular dystonia	American Academy of Oral Medicine (2018)
Focal limb dystonia - UE**	American Academy of Neurology (2008)
Essential tremor - UE	American Academy of Neurology (2008)
Sialorrhea	American Academy of Cerebral Palsy and Developmental Medicine (AACPDM, 2018); International Parkinson and Movement Disorder Society (2018)
OAB/urinary incontinence	American Urological Association Society of Urodynamics, Female Pelvic Medicine and Urogenital Reconstruction (2014, 2015)
<i>Gastrointestinal Conditions (see guidelines for required oral medication information)</i>	
Esophageal achalasia	American College of Gastroenterology (2013)
HD and IAS achalasia	American Pediatric Surgical Association (2017)
Chronic anal fissure	American College of Gastroenterology (2014)

*American Academy of Neurology (AAN) classifies Botox use for hemifacial spasm and motor tics as category C, and notes that data are inadequate to make a recommendation for lower limb dystonia. All other AAN Botox recommendations above are classified as category B - probably effective.

**Policy criteria requiring failure of oral medication for dystonias are limited to dystonias affecting the limbs (see Cloud and Jinnah, 2010).

V. Dosage and Administration

Indication	Dosing Regimen	Maximum Dose
CD	Divided among affected muscles every 12 weeks: Up to 1,000 Units IM	

Indication	Dosing Regimen	Maximum Dose
Adult upper and lower limb spasticity	Divided among affected muscles every 12 weeks: <ul style="list-style-type: none"> • Upper limb: Up to 1,000 Units IM • Lower limb: Up to 1,500 Units IM Upper and lower limbs: Up to 1,500 Units IM staying within per limb guidelines	See dosing regimens for maximum dose
Pediatric upper and lower limb spasticity	Divided among affected muscles every 12 weeks: <ul style="list-style-type: none"> • Upper limb: Up to the lower of 16 Units/kg/limb IM or 640 Units IM • Lower limb: Up to the lower of 15 Units/kg/limb IM or 1,000 Units IM • Bilateral lower limb: Up to the lower of 30 Units IM or 1,000 Units IM Upper and lower limbs: Up to the lower of 30 Units IM or 1,000 Units IM staying within per limb guidelines	<ul style="list-style-type: none"> • Esophageal achalasia: one treatment session every 24 weeks. • All other indications: one treatment session every 12 weeks.
Off-label uses		
Adults: OAB/urinary incontinence associated with neurologic condition	Up to 250 Units IM in the detrusor muscle per treatment session. <i>(Off-label - Irwin 2013)</i>	
Adults: chronic migraine	Up to 250 Units IM per treatment session. <i>(Off-label - Alipour 2016, Menezes 2007)</i>	
Adults: axillary hyperhidrosis	Up to 200 Units IM per treatment session. <i>(Off-label - Clinical Pharmacology, Heckmann 2001)</i>	
Adults: blepharospasm	Up to 60 Units IM per treatment session. <i>(Off-label - Hallet 2009, Micromedex, Truong 2008)</i>	
Adults: strabismus	Up to 20 Units IM per treatment session. <i>(Off-label - Bunting 2013, Talebnejad 2008)</i>	
Adults: chronic sialorrhea	Up to 250 Units IM per treatment session. <i>(Off-label - Guidubaldi 2011)</i>	
Adults: laryngeal dystonia	Up to 45 Units IM per treatment session. <i>(Off-label - Truong 2006, Guglielmino 2018)</i>	
Adults: OMD	Up to 100 Units IM per treatment session. <i>(Off-label - Hallet 2009)</i>	
Adults and pediatrics: UE dystonia Adults: UE essential tremor	Dose is supported by practice guidelines or peer-reviewed literature for the relevant off-label use and member age (prescriber must submit supporting evidence; number of Units per treatment session does not exceed the lower of 16 Units/kg body weight or 640 Units IM for pediatrics, or 1,000 Units IM for adults).	

Indication	Dosing Regimen	Maximum Dose
Adults: esophageal achalasia	Up to 250 Units IM per treatment session. (Off-label - Annese 1999)	
Adults and pediatrics: HD, IAS achalasia	Up to 200 Units IM per treatment session. (Off-label - Han-Geurts 2014, Roorda 2019)	
Adults: chronic anal fissure	Up to 100 Units IM per treatment session. (Off-label - Pilkington 2018)	

VI. Product Availability

Vial: 300 units, 500 units

VII. References

1. Dysport Prescribing Information. Basking Ridge, NJ: Ipsen Biopharmaceuticals, Inc.; July 2020. Available at www.dysport.com. Accessed January 11, 2021.
 2. AbobotulinumtoxinA. In: Micromedex. Ann Arbor, MI: Truven Health Analytics; 2020. Available from: www.micromedexsolutions.com. Accessed July 10, 2020.
 3. Clinical Pharmacology [database online]. Tampa, FL: Gold Standard, Inc.; 2020. Available at: <http://www.clinicalpharmacology-ip.com/>.
- Migraine, Spasticity, Dystonia, Tremor*
4. Albanese A, Bhatia K, Bressman SB, et al. Phenomenology and classification of dystonia: a consensus update. *Mov Disord*. June 15, 2013; 28(7): 863-873. doi:10.1002/mds.25475.
 5. Alipour A, Homam SM, Khorashadzadeh M, et al. The effect of abobotulinum toxin A in the prophylactic treatment of refractory migraine. *Turk J Neurol*. 2016;22:156-160. DOI:10.4274/tnd.15986.
 6. Bunting HJ, Dawson ELM, Lee JP, Adams GGW. Role of inferior rectus botulinum toxin injection in vertical strabismus resulting from orbital pathology. *Strabismus*. 2013 Sep;21(3):165-168. DOI:10.3109/09273972.2013.811602.
 7. Cloud LJ, Jinnah HA. Treatment strategies for dystonia. *Expert Opin Pharmacother* 2010; 11(1):5-15.
 8. France K, Stoopler ET. The American Academy of Oral Medicine clinical practice statement: Oromandibular dystonia. *Oral Med Oral Pathol Oral Radiol*, April 2018; 125 (4), 283-285.
 9. Guglielmino G, Teixeira de Moraes B, Villanova LC, et al. Comparison of botulinum toxin and propranolol for essential and dystonic vocal tremors. *Clinics (Sao Paulo)*. 2018 Jul 16;73:e87. DOI:10.6061/clinics/2018/e87.
 10. Hallett M, Benecke R, Biltzer A et al. Treatment of focal dystonias with botulinum neurotoxin. *Toxicon*, October 2009;54(5):628-633. DOI:10.1016/j.toxicon.2008.12.008.
 11. Menezes C, Rodrigues B, Magalhaes E, Melo A. Botulinum toxin type A in refractory chronic migraine: an open-label trial. *Arq Neuropsiquiatr*. 2007;65(3-A):596-598.
 12. Silberstein SD, Holland S, Freitag F et al. Evidence-based guideline update: Pharmacologic treatment for episodic migraine prevention in adults: Report of the Quality Standards Subcommittee of the American Academy of Neurology and the American Headache Society. *Neurology*. 2012; 78(17): 1337-1345.
 13. Simpson DM, Hallett M, Ashman EJ et al. Practice guideline update summary: botulinum neurotoxin for the treatment of blepharospasm, cervical dystonia, adult spasticity, and

- headache: Report of the Guideline Development Subcommittee of the American Academy of Neurology. *Neurology*. 2016; 86(19): 1818-1826.
14. Simpson DM, Gracies JM, Graham HK et al. Assessment: botulinum neurotoxin for the treatment of spasticity (an evidence-based review): Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. *Neurology*. 2008; 70(19): 1691-1698.
 15. Simpson DM, Blitzer A, Brashear A et al. Assessment: botulinum neurotoxin for the treatment of movement disorders (an evidence-based review): Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. *Neurology*. 2008; 70: 1699-1706.
 16. Stachler RJ, Francis DO, Schwartz SR, Damask CC, et al. Clinical practice guidelines: Hoarseness (Dysphonia) (Update). American Academy of Otolaryngology–Head and Neck Surgery Foundation 2018. 1-42. <https://doi.org/10.1177/0194599817751030>
 17. Talebnejad MR, Sharifi M, Nowroozzadeh MH. The role of botulinum toxin in management of acute traumatic third-nerve palsy. *J AAPOS*. 2008;12(5):510-513.
 18. Truong D, Comella C, Fernandez HH, et al: Efficacy and safety of purified botulinum toxin type A (Dysport) for the treatment of benign essential blepharospasm: a randomized, placebo-controlled, phase II trial. *Parkinsonism Relat Disord*. 2008;14(5):407-414.
 19. Truong DD, Bhidayasiri R. Botulinum toxin therapy of laryngeal muscle hyperactivity syndromes: comparing different botulinum toxin preparations. *European Journal of Neurology*. 2006;13 (Suppl. 1):36-41.

Sialorrhea

20. AACPDM Sialorrhea Care Pathway Team: L Glader (team lead), C Delsing, A Hughes, J Parr, L Pennington, D Reddihough, K van Hulst, J van der Burg. Sialorrhea in cerebral palsy. Available at: <https://www.aacpdm.org/publications/care-pathways/sialorrhea>. Available at: <https://www.aacpdm.org/publications/care-pathways/sialorrhea>. Last updated June 4, 2018. Accessed January 8, 2021.
21. Guidubaldi A, Fasano A, Ialongo T, et al. Botulinum toxin A versus B in sialorrhea: a prospective, randomized, double-blind, crossover pilot study in patients with amyotrophic lateral sclerosis or Parkinson’s disease. *Movement Disorders*. 2011;26(2):313-319.
22. Lakraj AA, Moghimi, Jabbari B. Sialorrhea: Anatomy, pathophysiology and treatment with emphasis on the role of botulinum toxins. *Toxins* 2013, 5, 1010-1031; doi:10.3390/toxins5051010.
23. Seppi K, Chahine L, Chaudhuri R et al. International Parkinson and Movement Disorder Society evidence-based medicine review: Update on treatments for the non-motor symptoms of Parkinson’s Disease. 2018. Available at <https://www.movementdisorders.org/MDS-Files1/Resources/PDFs/EBM-NMS-Final-Paper-August-2018.pdf>.
24. Sridharan K, Sivaramakrishnan G. Pharmacological interventions for treating sialorrhea associated with neurological disorders: A mixed treatment network meta-analysis of randomized controlled trials. *Journal of Clinical Neuroscience* 51 (2018) 12–17.
25. Young CA, Johnson EC, et al. Treatment for sialorrhea (excessive saliva) in people with motor neuron disease/amyotrophic lateral sclerosis. *Cochrane Database Syst Rev*. 2011 May 11;(5):CD006981. doi: 10.1002/14651858.CD006981.pub2.

Overactive Bladder, Urinary Incontinence

26. Gormley EA, Lightner DJ, Faraday M, Vasavada SP. Diagnosis and treatment of overactive bladder (non-neurogenic) in adults: AUA/SUFU guideline amendment. *Journal of Urology*. 2015; 193(5): 1572-1580.
27. Gormley EA, Lightner DJ, Burgio KL et al. Diagnosis and treatment of overactive bladder (non-neurogenic) in adults: AUA (American Urological Association)/SUFU guideline. American Urological Association Education and Research, Inc. Available at <http://www.auanet.org/education/guidelines/overactive-bladder.cfm>. Published May 2014. Accessed January 25, 2019.
28. Irwin P, Somov P, Ekwueme K. Patient reported outcomes of abobotulinumtoxinA injection treatment for idiopathic detrusor overactivity: a pragmatic approach to management in secondary care. *Journal of Clin Urol*. 2013;6:1.

Primary Axillary Hyperhidrosis

29. Heckmann M, Ceballos-Baumann AO, Plewig G. Botulinum toxin A for axillary hyperhidrosis (excessive sweating). *N Engl J Med*. 2001;344:488-493.
30. Pariser DM, Ballard A. Topical therapies in hyperhidrosis care. *Dermatol Clin*. October 2014; 32(4): 485-90. doi: 10.1016/j.det.2014.06.008. Epub 2014 Jul 29.

Sialorrhea

31. AACPDM Sialorrhea Care Pathway Team: L Glader (team lead), C Delsing, A Hughes, J Parr, L Pennington, D Reddihough, K van Hulst, J van der Burg. Sialorrhea in cerebral palsy. Available at: <https://www.aacpdm.org/publications/care-pathways/sialorrhea>. Available at: <https://www.aacpdm.org/publications/care-pathways/sialorrhea>. Last updated June 4, 2018. Accessed January 8, 2021.
32. Guidubaldi A, Fasano A, Ialongo T, et al. Botulinum toxin A versus B in sialorrhea: a prospective, randomized, double-blind, crossover pilot study in patients with amyotrophic lateral sclerosis or Parkinson's disease. *Movement Disorders*. 2011;26(2):313-319.
33. Lakraj AA, Moghimi, Jabbari B. Sialorrhea: Anatomy, pathophysiology and treatment with emphasis on the role of botulinum toxins. *Toxins* 2013, 5, 1010-1031; doi:10.3390/toxins5051010.
34. Seppi K, Chahine L, Chaudhuri R et al. International Parkinson and Movement Disorder Society evidence-based medicine review: Update on treatments for the non-motor symptoms of Parkinson's Disease. 2018. Available at <https://www.movementdisorders.org/MDS-Files1/Resources/PDFs/EBM-NMS-Final-Paper-August-2018.pdf>.
35. Sridharan K, Sivaramakrishnan G. Pharmacological interventions for treating sialorrhea associated with neurological disorders: A mixed treatment network meta-analysis of randomized controlled trials. *Journal of Clinical Neuroscience* 51 (2018) 12–17.
36. Young CA, Johnson EC, et al. Treatment for sialorrhea (excessive saliva) in people with motor neuron disease/amyotrophic lateral sclerosis. *Cochrane Database Syst Rev*. 2011 May 11;(5):CD006981. doi: 10.1002/14651858.CD006981.pub2.

Esophageal Achalasia

37. Annese V, Bassotti G, Coccia G, et al. Comparison of two different formulations of botulinum toxin A for the treatment of oesophageal achalasia. *Aliment Pharmacol Ther*. 1999;13:1347-1350.
38. Vaezi MF, Pandolfino JE, Vela MF. American College of Gastroenterology clinical guideline: Diagnosis and management of achalasia. *Am J Gastroenterol*. 2013; 108(8): 1238-1259.

Hirschsprung Disease, Internal Anal Sphincter Achalasia

39. Han-Geurts IJM, Hendrix VC, de Blaauw I, et al. Outcome after anal intrasphincteric Botox injection in children with surgically treated Hirschsprung disease. *JPGN*. November 2014;59(5):604-607.
40. Langer JC, Rollins, MD, Levitt M. Guidelines for the management of postoperative obstructive symptoms in children with Hirschsprung disease. *Pediatr Surg Int*, 2017; 33:523-526. DOI 10.1007/s00383-017-4066-7
41. Roorda D, Abeln ZAM, Oosterlaan J, et al. Botulinum toxin injections after surgery for Hirschsprung disease: Systematic review and meta-analysis. *World J Gastroenterol*. 2019 July 7;25(25):3268-3280. DOI:10.3748/wjg.v25.i25.3268

Chronic Anal Fissure

42. Pilkington SA, Bhome R, Welch RE et al. Bilateral versus unilateral botulinum toxin injections for chronic anal fissure: a randomised trial. *Techniques in Coloproctology*. 2018;22:545-551. <https://doi.org/10.1007/s10151-018-1821-2>.
43. Wald A, Bharucha AE, Cosman BC, et al. American College of Gastroenterology clinical guideline: Management of benign anorectal disorders. *Am J Gastroenterol* 2014; 109:1141–1157; doi: 10.1038/ajg.2014.190; published online 15 July 2014.

Coding Implications

Codes referenced in this clinical policy are for informational purposes only. Inclusion or exclusion of any codes does not guarantee coverage. Providers should reference the most up-to-date sources of professional coding guidance prior to the submission of claims for reimbursement of covered services.

HCPCS Codes	Description
J0586	Injection, abobotulinumtoxinA, 5 units

Reviews, Revisions, and Approvals	Date	P&T Approval Date
CD and upper limb spasticity for adults are split into separate criteria sets. Added CD definition and requirement of pain and functional impairment. Upper limb spasticity for adults is edited by adding lower limb spasticity indication, adding examples of muscle groups and an informational footnote, and changing the maximum dose from 1000 to 1500 per treatment session. Newly labeled pediatric lower limb spasticity added as an indication. Efficacy statement added under continuation criteria. Safety information removed. Dystonia information added at Appendix B. “Non-cosmetic” parenthetical added to the background FDA indication section and indication for glabellar lines is removed; cosmetic coverage restriction reworded under the “Other Diagnoses/Indications” section to include notation of glabellar lines.	06.17	07.17
2Q 2018 annual review: added physical medicine and rehabilitation specialist for all indications; aligned pediatric specialist requirement with adult spasticity indication; removed specific diagnostic requirements for	04.24.18	05.18

Reviews, Revisions, and Approvals	Date	P&T Approval Date
limb spasticity; combined Medicaid and Commercial lines of business; added HIM; Commercial: approval durations changed from length of benefit to 6 months initial and 12 months continued approval; references reviewed and updated.		
No significant changes, added maximum dose of 1,500 units per treatment session for adult lower limb spasticity for continued approval	12.19.18	
2Q 2019 annual review: no significant changes; references reviewed and updated.	02.15.19	05.19
RT4: added use for pediatric upper limb spasticity and updated dosing per updated Dysport prescribing information; references reviewed and updated.	11.06.19	
2Q 2020 annual review: cerebral palsy included in spasticity criteria set without restriction; rehabilitation specialist incorporated under physiatrist; previous (last 12 weeks) or concurrent toxin product use restriction added to all initial/continuation criteria; dosing updated per package insert; same-visit treatment for multiple indications is limited to upper/lower limb spasticity (Section III); references reviewed and updated.	03.02.20	05.20
RT4: updated FDA approved indication for spasticity which now includes cerebral palsy for upper limb spasticity in pediatric patients.	07.15.20	
2Q 2021 annual review: treatment plan requirement detailing number of Units per site and treatment session is changed to per indication and treatment session; treatment of multiple indications restriction removed and replaced with total treatment dose limitation (Section III); off-label uses added as follows per previously approved clinical guidance: adults (OAB/urinary incontinence, migraine, AH, blepharospasm, strabismus, sialorrhea, LD, OMD, UE dystonia, UE essential tremor; EA, HD, IAS achalasia, CAF; updated reference for HIM off-label use to HIM.PA.154 (replaces HIM.PHAR.21); references reviewed and updated.	01.14.21	05.21
Revised continued therapy max dose for chronic migraine from 155 units to 250 units; allowed continued approval of sialorrhea from 12 weeks to 16 weeks to match initial approval duration; clarified continued approval duration for esophageal achalasia for 2 nd dose vs beyond.	09.23.21	

Important Reminder

This clinical policy has been developed by appropriately experienced and licensed health care professionals based on a review and consideration of currently available generally accepted standards of medical practice; peer-reviewed medical literature; government agency/program approval status; evidence-based guidelines and positions of leading national health professional organizations; views of physicians practicing in relevant clinical areas affected by this clinical policy; and other available clinical information. The Health Plan makes no representations and accepts no liability with respect to the content of any external information used or relied upon in developing this clinical policy. This clinical policy is consistent with standards of medical practice current at the time that this clinical policy was approved. “Health Plan” means a health

plan that has adopted this clinical policy and that is operated or administered, in whole or in part, by Centene Management Company, LLC, or any of such health plan's affiliates, as applicable.

The purpose of this clinical policy is to provide a guide to medical necessity, which is a component of the guidelines used to assist in making coverage decisions and administering benefits. It does not constitute a contract or guarantee regarding payment or results. Coverage decisions and the administration of benefits are subject to all terms, conditions, exclusions and limitations of the coverage documents (e.g., evidence of coverage, certificate of coverage, policy, contract of insurance, etc.), as well as to state and federal requirements and applicable Health Plan-level administrative policies and procedures.

This clinical policy is effective as of the date determined by the Health Plan. The date of posting may not be the effective date of this clinical policy. This clinical policy may be subject to applicable legal and regulatory requirements relating to provider notification. If there is a discrepancy between the effective date of this clinical policy and any applicable legal or regulatory requirement, the requirements of law and regulation shall govern. The Health Plan retains the right to change, amend or withdraw this clinical policy, and additional clinical policies may be developed and adopted as needed, at any time.

This clinical policy does not constitute medical advice, medical treatment or medical care. It is not intended to dictate to providers how to practice medicine. Providers are expected to exercise professional medical judgment in providing the most appropriate care, and are solely responsible for the medical advice and treatment of members. This clinical policy is not intended to recommend treatment for members. Members should consult with their treating physician in connection with diagnosis and treatment decisions.

Providers referred to in this clinical policy are independent contractors who exercise independent judgment and over whom the Health Plan has no control or right of control. Providers are not agents or employees of the Health Plan.

This clinical policy is the property of the Health Plan. Unauthorized copying, use, and distribution of this clinical policy or any information contained herein are strictly prohibited. Providers, members and their representatives are bound to the terms and conditions expressed herein through the terms of their contracts. Where no such contract exists, providers, members and their representatives agree to be bound by such terms and conditions by providing services to members and/or submitting claims for payment for such services.

Note:

For Medicaid members, when state Medicaid coverage provisions conflict with the coverage provisions in this clinical policy, state Medicaid coverage provisions take precedence. Please refer to the state Medicaid manual for any coverage provisions pertaining to this clinical policy.

©2016 Centene Corporation. All rights reserved. All materials are exclusively owned by Centene Corporation and are protected by United States copyright law and international copyright law. No part of this publication may be reproduced, copied, modified, distributed, displayed, stored in a retrieval system, transmitted in any form or by any means, or otherwise

published without the prior written permission of Centene Corporation. You may not alter or remove any trademark, copyright or other notice contained herein. Centene[®] and Centene Corporation[®] are registered trademarks exclusively owned by Centene Corporation.